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Abstract:  
 
This review addresses the role of hypertension in precipitating Calcific aortic 
valve disease (CAVD) and the therapeutic potential of anti-hypertensive interventions 
to ameliorate CAVD. CAVD was originally considered to be a degenerative disease 
representing the “wear and tear” of the aortic valves. More recently both conceptually 
and experimentally, CAVD has come to be considered the result of an active disease 
process. Whilst, there are some common factors in the pathology and risk factors for 
atherosclerosis and CAVD there are also some distinct differences. Hypertension is an 
established risk factor for coronary artery disease and has been recognised as a risk 
factor for CAVD. Angiotensin converting enzyme inhibitors have been found to have 
beneficial effects in CAVD and as in atherosclerosis such effects may be due to the 
blood pressure lowering action but also to direct pleiotropic effects on the 
biochemical and cellular mechanisms of disease progression in the respective tissues. 
The very high prevalence of hypertension in the community coupled with an aging 
population, a risk factor associated with both hypertension and CAVD, infers that 
hypertension will be one of the predominant factors that increase the impact of CAVD 
on human health in the coming decades.  
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INTRODUCTION 
Calcific aortic valve disease (CAVD) is a progressive condition which leads to 
significant symptomatology and death if untreated. The prevalence of CAVD is 
increasing because of our increasingly elderly population. Currently 2-5% of very 
elderly patients are diagnosed with CAVD [1, 2] which carries an 80% 5 year risk of 
progression to heart failure, valve replacement or death [3].  CAVD is also the second 
most common indication for cardiac surgery in the Western world [4].  
Initially thought to be a degenerative disorder of aging, increasingly specific risk 
factors are being identified in association with CAVD. Age, male gender, 
hypertension and current smoking have all been found to be associated with CAVD in 
a large population cohort study.  Correlations have also been found between CAVD 
and elevated levels of lipoprotein and low density lipoprotein cholesterol.  Other 
identified risk factors are diabetes, and elevated body mass index [5] and end stage 
renal disease [6]. 
As stated above, CAVD was originally considered to be a degenerative disease 
representing the “wear and tear” of the hard working aortic valves [7]. More recently 
conceptually and experimentally CAVD has come to be considered the result of an 
active disease process with the implication that it may be amenable to therapeutic 
intervention [8, 9]. The major observations indicating that CAVD is an active disease 
process are the deposition of lipid in early lesions, specifically lipids associated with 
atherosclerosis,  the presence of monocyte macrophages and other cells of the 
immune system [9], the presence and involvement of proteins associated with 
calcification [10] and the presence of the components of the Renin Angiotensin 
System (RAS) including angiotensin converting enzyme (ACE), angiotensin II (AII) 
and angiotensin receptors [9, 11]. CAVD has a catastrophic impact on the appearance 
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of the valve leaflets (Fig. 1). Current concepts suggest an analogy between the 
pathological mechanisms of atherosclerosis [8] and CAVD however only 50% of 
patients with severe aortic stenosis have appreciable coronary disease, so clearly some 
differences must be present in the aetiology [12]. There are some common factors as 
well as distinct differences in the pathology and risk factors for atherosclerosis and 
CAVD. In atherosclerosis, the arterial neo-intima is the location of the formation of 
atherosclerotic plaques whereas CAVD disease commences within the boundaries of 
the valve and ultimately forces an expansion of the valve tissue [13]. Also, 
angiotensin receptors are expressed in VSMCs in the wall of normal vessels [14] but 
are not expressed by aortic valve myofibroblasts (avMs) in normal aortic valves [8].  
There are however common factors as well. There is a large amount of literature 
on the relationship between hypertension and cardiovascular disease but very little on 
the mechanisms through which hypertension accelerates atherosclerosis. There is also 
only a small amount of information on the association and underlying mechanisms 
linking CAVD and hypertension. Hypertension is a strong and well-established risk 
factor for coronary artery disease and has been recognised as a risk factor for CAVD. 
Multiple trials have demonstrated the benefits of blocking RAS in preventing 
atherosclerosis-related cardiovascular disease [15-17]. However, as in the case that 
the hyperglycaemia of diabetes is more than just elevated blood glucose [18], 
hypertension seems to be more than just elevated blood pressure [19]. Studies on the 
relationship of systolic blood pressure and atherosclerosis show that more than 
pressure per se is involved [19] and by analogy with the role of insulin resistance in 
diabetes, the stimulus for the hypertension is strongly implicated. The major stimulus 
is the RAS and manipulations of the RAS system have a direct impact of 
atherosclerotic lesion size [19]. Angiotensin converting enzyme (ACE) inhibitors 
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have been found to have beneficial effects, but not unequivocally, in CAVD. As in 
atherosclerosis, such beneficial effects in CAVD may be due to the anti-hypertensive 
action and also pleiotropic effects directly on the biochemical and cellular 
mechanisms of disease progression [20]. The very high prevalence of hypertension in 
the community [21] coupled with the aging of the population which is associated with 
both hypertension and CAVD, infers that hypertension will be one of the major 
underlying factors that increase the impact of CAVD on human health in coming 
decades. This review addresses the role of hypertension in precipitating CAVD and 
the potential for therapeutic benefit of anti-hypertensive interventions to ameliorate 
CAVD.  
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ANATOMY AND PATHOLOGY OF CAVD 
 
The processes causing the initiation and progression of aortic valve disease have 
not been clearly identified. Aortic valves have three distinct anatomical layers. These 
layers commencing from the upper or aortic side of the leaflet are the fibrosa, the 
spongiosa and the ventricularis and these are comprise predominantly collagen, 
glycosaminoglycans and elastin, respectively (see Fig. 2A). Pathologically, there are 
similarities but distinct differences between CAVD and atherosclerosis. The most 
important similarity is the co-localization of lipids with the proteoglycans, biglycan 
and decorin, in early CAVD and atherosclerosis [22-24]. Extracellular matrix (ECM) 
changes are characteristic of both atherosclerotic vessels and diseased aortic valves.  
Lipid-rich lesions accumulate predominately on the aortic surface of the valve [9], the 
basement membrane/elastic lamina beneath these lesions appears to be damaged or 
absent.  The collagenous fibrosa becomes thickened [9], partially due to the 
infiltration of lipids.  Proteoglycans, specifically the chondroitin/dermatan sulfate 
proteoglycans, biglycan, decorin, and versican, show increased abundance in early 
through late aortic valve lesions and biglycan and decorin are co localized with apoE 
and apoB  [22, 23] (Fig. 2B). A fundamental difference is the development of 
atherosclerosis in the neointima of coronary arteries whereas in aortic valve pathology 
the neo-intima does not have an anatomical equivalent [13]. Other differences 
between aortic valve disease and atherosclerosis are the deposition of lipid in the sub-
endothelial fibrosa layer in aortic valves but not in deeper layers, and calcification 
instead of necrosis as a response to lipid trapped in the valvular tissue  [23, 25, 26].   
Lipids, oxidized lipids, lipoproteins (Low Density Lipoproteins (LDL) and 
Lipoprotein (a)), and cholesterol are present in lesions of human sclerotic and stenotic 
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aortic valves, as well as in underlying regions of collagenous fibrosa [8, 9, 26, 27] 
characterized by elastic lamina fragmentation, macrophages, and accumulation of 
glycosaminoglycans (GAG) and proteoglycans [22, 23, 27].  
Some signaling studies have provided evidence on the pathways involved in 
CAVD that may represent therapeutic targets. Interestingly these pathways are 
distinct from those associated with vascular smooth muscle and atherosclerosis and 
further studies in this area may provide for interesting new leads possibly in both 
pathologies. A pathway identified in CAVD pathology but only associated with 
vascular development and not yet vascular disease is the canonical Wnt pathway [28, 
29]. Low density receptor-related protein (Lrp) binds to the secreted glycoprotein Wnt 
(a key regulator of bone formation) and frizzled receptors that subsequently activate 
β-catenin as part of the known signaling pathway in bone mineralization [30]. Wnts 
are highly secreted, cysteine-rich glycoproteins that are highly conserved among 
species. They bind to frizzled receptors (Fz) and can be inhibited by frizzled-related 
proteins (FRP) [29]. VSMCs have been found to express Wnt-5a, Fz-1,2,3 receptors 
and two inhibitors, FRP-1 and FRP-3 [29]. Although not much is known about the 
role of Wnt signalling in the vasculature, some studies have demonstrated its role in 
normal and pathological vessel growth and VSMC proliferation, where Wnt 
signalling requires the co-receptor, LRP6 [31]. 
There is substantial evidence that CAVD involves inflammatory processes as 
has been demonstrated for atherosclerosis, the latter especially in the presence of 
diabetes [32].  Lesions from early aortic valve sclerosis as well as from advanced 
calcific stenosis contain macrophages, T-lymphocytes, and mast cells [9, 33].  
VCAM-1, which is not normally expressed in aortic valve leaflets, is expressed on the 
endothelium of calcific aortic valves [34]. Inflammatory cytokines, including IL-1β, 
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TNF-α, IL-2, HLA-DR and C-reactive protein are also present in valve lesions [8, 
35].  
The aortic valve tissue response to injury is similar to other tissues with initial 
elevated TGF-β levels that have been shown in aortic valves myofibroblasts (avM)s 
in vitro to increase SM α-actin expression, stress fibre formation, contraction, 
collagen and hyaluronan (HA) synthesis, and secretion of sulfated GAGs [36]. TGF-β 
can signal through several pathways, classically via high affinity binding to TGF-βRII 
which recruits the kinase ALK5 (TGF-βRI). ALK5 phosphorylates the carboxy 
terminal Ser residues of the intracellular signal transducers, SMAD-2 and -3, leading 
to the formation of phospho-SMADs which form complexes with co-Smads and 
translocate to the nucleus where they act as transcription factors to activate or repress 
gene expression.  TGF-β is also able to activate the MAP-kinases ERK, JNK and p38. 
We have recently demonstrated that the action of TGF-β on VSMCs in atherosclerosis 
involves Smad-2 phosphorylation and activation of p38 MAP kinase [37]. The 
specific TGF-β pathways in avMs and particularly those participating in CAVD have 
yet to be elucidated.  
The Renin Angiotensin System (RAS) also contributes to the development of 
aortic valve sclerosis and stenosis [8].   ACE and angiotensin II are co localized with 
ApoB in valve lesions [11].  The angiotensin-1 receptor, present in normal healthy 
arteries but not normally expressed in heart valves, is also present in these lesions. 
There is in vitro evidence that these peptides can be synthesized within the valve [38]. 
 The formation of calcific nodules is a defining pathological occurrence in 
advanced late-stage valvular sclerotic lesions and results in the leaflets becoming stiff 
and the valve stenotic which precipitates the clinical condition of CAVD. Calcific 
nodules are found in association with oxidized lipids both in diseased human valves 
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and in animal models of CAVD.  Not surprisingly, calcific leaflets contain osteoblast-
like cells [33] and an abundance of several osteogenic mediators, including alkaline 
phosphatase, osteocalcin, osteopontin, BMPs, and MMP2 [39, 40].   
Prolonged in vitro culture of avMs leads to the spontaneous formation of calcific 
nodules and again TGF-β plays a prominent role in this stage of disease development 
[41].  In a specific association with a manifestation of hypertension, avMs exposed to 
elevated cyclic pressures downregulate the expression of osteopontin; since this agent 
is protective against mineralization, its down regulation may potentiate calcification 
[42].  
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ASSOCIATION OF HYPERTENSION AND CAVD 
 
The association between CAVD and clinical and biochemical factors has been 
investigated in several studies [1, 43]. Lindroos et al. [43] compared the occurrence of 
aortic valve disease in elderly subjects as established by echocardiographic and 
Doppler techniques with the existence of various biochemical and clinical parameters. 
They investigated 577 subjects ranging from 55-86 years of age. Twenty one subjects 
(4%) had severe aortic stenosis but 40% and 13% had slight and severe calcification, 
respectively [43]. Multivariate analysis identified several factors including 
hypertension which was shown to be an independent and highly statistically 
significant predictor of CAVD. The odds ratio for hypertension was 1.74 ( 95% 
confidence limits of 1.19-2.55) indicating a 74% higher rate of association when 
hypertension is present. This compares with an 89% increase for a 10 year increase in 
age and interestingly a 39% increase for each 5 kg.m-2 decrease in body mass index, 
the latter associating leanness with predisposition to CAVD. In this study, factors 
including gender and diabetes were not correlated with aortic valve calcification [43].  
In the Cardiovascular Health Study, Otto and colleagues [1] investigated the 
prevalence of aortic sclerosis and stenosis in the elderly and the clinical factors 
associated with CAVD. The study covered a randomly chosen group of more than 
5000 elderly subjects (≥ 65 years) who underwent 2D echocardiographic investigation 
and these results were analysed by stepwise logistic regression analysis with a range 
of clinical parameters [1]. In the entire group, aortic sclerosis and stenosis were 
present at 26% and 2%, respectively. Disease rates were approximately 50 per cent 
higher in the group ≥ 75 years of age. A history of hypertension established on a self-
reported basis was associated with an excess odds ratio of 1.23 (95% confidence 
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limits of 1.14-1.32) establishing a highly statistically significant 23% increase in risk.   
This compares with an increase of 118 % for each 10 year increase in age, 103% for 
male gender and 35 % increase for smoking as independent predictors of aortic valve 
disease. LDL cholesterol, a strong predictor of coronary artery disease had an odds 
ratio for association with aortic sclerosis and stenosis of 1.12 (95% confidence limits 
of 1.03-1.23) indicating modest but statistically significant association of this 
parameter for both coronary artery disease and CAVD [1].  
 
HYPERTENSION AND ATHEROSCLEROSIS: RELEVANCE TO CAVD 
 
Hypertension is recognised as one of the strongest independent risk factors for 
cardiovascular disease [44, 45] and treatments for hypertension are highly efficacious 
in the prevention of cardiovascular events [15-17]. Hypertension, like other risk 
factors such as hyperglycaemia, accelerates atherosclerosis leading to increased rates 
of cardiovascular disease [13, 46]. It is surprising but there is little information on the 
mechanisms by which hypertension accelerates atherosclerosis. Historically, studies 
in animal models in the 1980s particularly those that used the spontaneous 
hypertensive rat (SHR) and its normotensive Wistar Kyoto (WKY) controls, focused 
on the mechanism of hypertension per se and specific parameters such as the 
development of vascular hypertrophy [47, 48]. Rats are particularly resistant to the 
development of atherosclerosis and SHR do not develop atherosclerotic lesions. More 
recent studies have focused on the genetically modified mice (ApoE-/- and LDLR-/-) 
which develop atherosclerosis on high fat diets and the mechanisms of the 
development of lesions in those mice but the impact of hypertension has not attracted 
great attention [49]. A major reason for the lack of mechanistic studies on the 
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association of hypertension and atherosclerosis is due to the fact that hypertension is 
obviously an in vivo phenomenon which cannot be reproduced in cell culture. There 
have been studies of blood flow and shear stress and also of cell stretching which 
partially mimic the parameters associated with hypertension but none is a suitable 
comprehensive model of hypertension [50, 51].  
One of the strongest factors linking hypertension and the accelerated 
development of atherosclerosis is the activation of the RAS [11]. The RAS is up 
regulated in hypertension and cardiovascular disease and blocking this system at 
multiple levels abrogates the development of cardiovascular disease. There is 
considerable evidence that the actions of the major hormonal effector of the RAS, 
AII, not only increase blood pressure but also has a range of direct actions which are 
deleterious to the cardiovascular system. However, based on the multiple roles of AII 
in causing hypertension, the actions of AII can somewhat narrowly be used as a 
surrogate for studies of hypertension and the development of atherosclerosis and also 
potentially for considering the role of hypertension in the development of aortic 
sclerosis and stenosis.  
AII is a potent activator of a wide range of actions on VSMCs which are 
associated with the development of atherosclerosis [52, 53]. AII stimulates the 
production and modifies the structure of proteoglycans by vascular smooth muscle 
cells (VSMCs) [54, 55]. These proteoglycans play a critical early role in 
atherosclerosis through the trapping of lipoproteins in the vessel wall [24, 56, 57]. AII 
stimulates the production of reactive oxygen species (ROS) and also many facets of 
the inflammatory response including the secretion of cytokines and adhesion 
molecules [58].  
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There is one major difference between the potential role of AII in 
atherosclerosis and CAVD. VSMCs in the vessel wall express high levels of 
angiotensin receptors (associated with vessel tone) and cultured VSMCs express 
angiotensin receptors to variable levels. In contrast, the avMs of normal aortic valves 
do not express angiotensin receptors. Unlike VSMCs, early passage avMs do not 
respond to AII by increasing proteoglycan production (P.J. Little, unpublished 
observations) [54]. Diseased aortic valves express angiotensin receptors [11]. Thus 
there would appear to be a clear difference that AII may contribute to early 
atherosclerosis but as previously proposed its role is likely to be later in the CAVD 
process [8]. There may be considerably different opportunities for therapeutic 
intervention in atherosclerosis and CAVD and the underlying pathology will often 
render earlier intervention preferable in preventing disease initiation and progression. 
Thus, ACE inhibitors and angiotensin receptor blockers (ARB) may be particularly 
beneficial in early atherosclerosis (due to effects on blood pressure and direct 
protective effects on the vasculature). However, the absence of the expression of 
angiotensin receptors in normal aortic valves might imply that these agents may not 
have beneficial effects on valves in the early stages of disease development and this is 
one issue that needs to be resolved clinically [8]. However, it should be appreciated 
that other potentially beneficial effects of RAS blockade on cardiovascular pathology 
should not be excluded and the role of blocking the RAS system in preventing CAVD 
and its consequences should be further investigated and clarified.  
Rosenhek et al. reported that ACE inhibitors do not appear to slow the 
progression of aortic stenosis at a time when statin therapy does have an impact [59]. 
In view of the expression of angiotensin receptors in avMs in diseased aortic valves 
this result is quite surprising. Furthermore, the effect of statins may not be related to 
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plasma cholesterol lowering and may relate to the anti-inflammatory actions of 
statins. As ACE inhibitors also have anti-inflammatory actions [60], perhaps the anti-
inflammatory profiles of ACE inhibitors and statins are sufficiently different to 
provide some efficacy for statins over ACE inhibitors in CAVD? Clearly further in 
vitro and in vivo studies as well as clinical trials are required to determine the impact 
of drugs on the development and progression of aortic valve sclerosis and stenosis. 
This includes in clinical setting consideration of the timing of any therapeutic 
intervention which may not necessarily mean only early therapeutic intervention.     
 
ANTI-HYERTENSIVE THERAPY AND PREVENTION OF CAVD 
 
The conjunction of hypertension and CAVD was initially thought to represent a 
therapeutic conundrum and historically ACE inhibition was considered to be 
contraindicated in patients with aortic stenosis. It could be reasoned that therapeutic 
peripheral vasodilatation coupled with compromised cardiac output due to aortic 
valve stenosis could potentially lead to circulatory collapse. However, although the 
reasons are unclear, the results of numerous studies indicate that this is a theoretical 
rather than practical issue [61]. Furthermore, many patients with aortic valve stenosis 
or at least severe aortic valve sclerosis will already be on blood pressure lowering 
therapy without apparent compromise. Considerable evidence conclusively indicates 
that inhibition of the RAS with ACE inhibitors or ARBs has favourable effects on the 
cardiovascular system, particularly the prevention of left ventricular hypertrophy and 
cardiac remodelling, both of which are strong risk factors for cardiac disease. 
Although further information is required before a definite position can be adopted it 
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would appear that the cardiovascular benefits of RAS inhibition may outweigh the 
potential for negative outcomes in patients with aortic valve stenosis. 
There are no prospective studies available only retrospective observational 
studies of RAS inhibition and CAVD progression. A recent observational study 
investigated the relationship between the rate of change of volumetric aortic valve 
calcium (AVC) scores of patients receiving or not receiving ACE inhibitors [62]. The 
study investigated 123 patients of whom 43 were on ACE inhibitors and the mean 
study time was 2.5 years [62]. The patients had undergone two serial electron beam 
computed tomography (CT) investigations. The rates of change (increase) of AVC 
scores were statistically significantly higher in the group of patients not receiving 
ACE inhibitors. The rates of increasing calcium deposition for patients not receiving 
and those receiving ACE inhibitors were 28.7 %/yr and 11.0 %/yr, respectively. The 
adjusted odds ratio was a highly significant 29 % in favour of the group on ACE 
inhibitors. Of interest the prevalence of hypertension was high and the baseline AVC 
score was statistically significantly higher (146.3 versus 69.5) in the group of patients 
on ACE inhibitors [62]. It was noted that the association of decreased rates of AVC 
progression with ACE inhibitors therapy was maintained after adjustment for the 
higher baseline level of AVC in the ACE inhibitor group. Although a careful 
interpretation is appropriate this study in total suggests a role for hypertension in 
precipitating CAVD and a potential role of ACE inhibitors in slowing the progression 
of disease even in the presence of ongoing hypertension.    
Rosenhek et al. have retrospectively evaluated the impact of ACE inhibitors and 
statins on the progression of aortic stenosis [59]. Of 211 patients, average age 70 
years, with confirmed aortic stenosis (peak velocity >2.5 m/s)  and otherwise normal 
cardiac physiology receiving two echocardiograms separated by an average of 24±18 
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months 102 were on ACE inhibitors, 50 patients on statins and 32 patients on both 
agents [59]. The increase in annualised peak aortic jet velocity for the entire study 
group was 0.32±0.44 m.s-1.y-1. ACE inhibitors had no effect on this rate of disease 
progression either alone or in combination with statin therapy. For comparison, statin 
therapy markedly and statistically significantly reduced the rate of progression to 
0.10±0.41 m.s-1.y-1. and this effect of statins was present in patients with both mild-to-
moderate and severe aortic stenosis. In this study 80 percent of the patients had 
hypertension possibly pointing to a role of hypertension in the development of CAVD 
notwithstanding the lack of efficacy of ACE inhibitor therapy [59].  
 
CONCLUSIONS 
 
CAVD is now appropriately recognised as a formal disease process and not a 
result of nonspecific wear and tear based aging of the leaflets. Hypertension is one of 
the most potent risk factors for atherosclerotic cardiovascular disease and a limited 
amount of data strongly suggests that hypertension is also associated with the 
development of CAVD. The development of CAVD has similarities with that of the 
known processes underlying the development of atherosclerosis but there are 
appreciable differences in the anatomy, cell biology and indeed based on a limited 
amount of data, on the response therapeutic interventions. The use of the many classes 
of anti-hypertensive agents does not give a uniform or consistent response in terms of 
slowing the development of atherosclerosis and preventing cardiovascular disease. It 
is preferable at this time that analogies between CAVD and atherosclerosis not be 
taken too strongly, lest potential treatments for CAVD, related and unrelated to 
hypertension, be overlooked. However, as always, account must be taken of the range 
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of actions of drugs on the whole cardiovascular system and not just the disease 
process in the aortic valve leaflets with the aim of optimising the patient outcome 
when hypertension and CAVD are present. 
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FIGURES AND FIGURE LEGENDS 
 
Figure 1.  
 
Picture of a complete diseased aortic valve from a patient who underwent aortic valve 
replacement at The Alfred, Melbourne, Australia in mid 2007. The three leaflets 
shown are typical and representative of valves from such patients. The view is from 
the upper or aortic side and the scale shows major divisions in centimetres.  
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Figure 2A. Stylised structure of a normal aortic valve leaflet 
The aortic valve is covered with a layer of endothelial cells which sit on a basement 
membrane. The elastic lamina lies under the basement membrane. The valve has three 
layers comprised predominantly of extracellular matrix - the fibrosa layer containing 
collagen, the spongiosa layer containing glycosaminoglycans (proteoglycans and 
hyaluronan) and the ventricularis containing elastin. The aortic myofibroblasts are 
mainly present in the elastin layer, with a random occurrence in the spongiosa. avMs 
reside mostly across the width of the leaflet but also form perpendicular bundles 
which make up a cross network in the valve. As drawn, the valve is joined to the 
heart/aorta at the back of the diagram. The figure here shows a valve leaflet dissected 
vertically two thirds from the back. The key to the components is shown under Fig. 
2B. 
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Figure 2B. Stylised structure of a severely effected leaflet from a stenotic aortic valve. 
In the early stage of CAVD (not shown), the basement membrane is disrupted, 
endothelial cells are lost and the surface is exposed. The upper elastic lamina gets 
pushed down as the lesion forms. The lesion contains a large amount of 
glycosaminoglycans (proteoglycans and hyaluronan). Monocytes in the blood migrate 
into the valve where they differentiate to form macrophages. Macrophages 
accumulate lipid leading to foam cell formation. The lesion also contains free lipid 
droplets.  In the end stage of the disease, the thickness of the valve increases. A 
calcified layer comprising protein and calcium deposits is formed at the base of the 
lesion. The lesion expands upwards and above the surface of the valve. The top 
section of the lesion may contain only a few endothelial cells. A photograph of the 3 
leaflets of a severely diseased aortic valve is shown in Figure 1.  
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